Polymeric nanobiotics as a novel treatment for mycobacterial infections

Batalha, Íris L.; Bernut, Audrey; Schiebler, Mark; Ouberaï, Myriam; Passemar, Charlotte; Klapholz, Catherine; Kinna, Sonja; michel, Sarah; Sader, Kasim; Castro‐Hartmann, Pablo; Renshaw, Stephen A.; Welland, Mark E.; Floto, R. Andres

doi:10.1016/j.jconrel.2019.10.009

Cited by 26 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Along with modulation of size, form and physicochemical properties of the polymer, to functionalize PNs with specific ligands may actively drive drugs to site-specific for the efficient drug uptaking, thereby readily reaching therapeutic intracellular levels [ 5 , 9 , 12 , 29 , 30 , 31 ]. Moreover, the PNs are extremely versatile in controlling the drug release profile.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

2020

View full text Add to dashboard Cite

Polymeric nanocarriers (PNs) have demonstrated to be a promising alternative to treat intracellular infections. They have outstanding performance in delivering antimicrobials intracellularly to reach an adequate dose level and improve their therapeutic efficacy. PNs offer opportunities for preventing unwanted drug interactions and degradation before reaching the target cell of tissue and thus decreasing the development of resistance in microorganisms. The use of PNs has the potential to reduce the dose and adverse side effects, providing better efficiency and effectiveness of therapeutic regimens, especially in drugs having high toxicity, low solubility in the physiological environment and low bioavailability. This review provides an overview of nanoparticles made of different polymeric precursors and the main methodologies to nanofabricate platforms of tuned physicochemical and morphological properties and surface chemistry for controlled release of antimicrobials in the target. It highlights the versatility of these nanosystems and their challenges and opportunities to deliver antimicrobial drugs to treat intracellular infections and mentions nanotoxicology aspects and future outlooks.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

2020

View full text Add to dashboard Cite

show abstract

“…However, the CFU-based method is time-consuming and could provide inconsistent results. Therefore, luminescence-based strategies have been proposed for rapid intracellular assays, particularly for testing antitubercular drugs [ 62 , 63 , 64 ]. Additionally, several methods for DST by flow cytometry have been developed, and more details are given below.…”

Section: Static Intracellular Infection Modelsmentioning

confidence: 99%

“…Examples include, but are not limited to, novel drug delivery systems, as is the case of nebulized liposomes for pulmonary targeting [ 26 , 42 , 43 , 48 , 66 , 67 , 68 , 69 ], nano-formulations and polymeric particles [ 64 , 70 , 71 ], and chemical compounds restoring antimicrobial susceptibility, among which efflux pump inhibitors deserve to be mentioned [ 72 , 73 ].…”

Section: Static Intracellular Infection Modelsmentioning

confidence: 99%

“…The ZF offers the possibility to image host-pathogen interactions at a cellular level, due to its transparency and existing recombinant bacterial strains that express fluorescent proteins [ 161 ] or are bioluminescently tagged [ 157 ]. Additionally, bacterial burdens can be analyzed with a fluorescent pixel count by fluorescence microscopy [ 64 ]. This technique correlates well with the results of CFU count after the plating of infected embryos [ 166 ].…”

Section: Animal Models In Preclinical Drug Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

et al. 2020

View full text Add to dashboard Cite

Nontuberculous mycobacteria (NTM) represent an increasingly prevalent etiology of soft tissue infections in animals and humans. NTM are widely distributed in the environment and while, for the most part, they behave as saprophytic organisms, in certain situations, they can be pathogenic, so much so that the incidence of NTM infections has surpassed that of Mycobacterium tuberculosis in developed countries. As a result, a growing body of the literature has focused attention on the critical role that drug susceptibility tests and infection models play in the design of appropriate therapeutic strategies against NTM diseases. This paper is an overview of the in vitro and in vivo models of NTM infection employed in the preclinical phase for early drug discovery and vaccine development. It summarizes alternative methods, not fully explored, for the characterization of anti-mycobacterial compounds.

show abstract

“…Nanomedicine is one possible solution for improving DNA delivery. In addition to vaccines, nanobiotics have been suggested to improve delivery of therapeutics against TB (Batalha et al, 2019).…”

Section: Zebrafish As a Model For Vaccine Deliverymentioning

confidence: 99%

Integrating fish models in tuberculosis vaccine development

Saralahti

Uusi-Mäkelä

Niskanen

et al. 2020

Disease Models &Amp; Mechanisms

View full text Add to dashboard Cite

Tuberculosis is a chronic infection by Mycobacterium tuberculosis that results in over 1.5 million deaths worldwide each year. Currently, there is only one vaccine against tuberculosis, the Bacillus Calmette–Guérin (BCG) vaccine. Despite widespread vaccination programmes, over 10 million new M. tuberculosis infections are diagnosed yearly, with almost half a million cases caused by antibiotic-resistant strains. Novel vaccination strategies concentrate mainly on replacing BCG or boosting its efficacy and depend on animal models that accurately recapitulate the human disease. However, efforts to produce new vaccines against an M. tuberculosis infection have encountered several challenges, including the complexity of M. tuberculosis pathogenesis and limited knowledge of the protective immune responses. The preclinical evaluation of novel tuberculosis vaccine candidates is also hampered by the lack of an appropriate animal model that could accurately predict the protective effect of vaccines in humans. Here, we review the role of zebrafish (Danio rerio) and other fish models in the development of novel vaccines against tuberculosis and discuss how these models complement the more traditional mammalian models of tuberculosis.

show abstract

Polymeric nanobiotics as a novel treatment for mycobacterial infections

Cited by 26 publications

References 35 publications

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

Integrating fish models in tuberculosis vaccine development

Contact Info

Product

Resources

About